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Abstract
Capsular polysaccharides (CPS) are a major virulence factor in meningococcal infections and form the basis for serogroup
designation and protective vaccines. Our work has identified meningococcal CPS as a pro-inflammatory ligand that
functions through TLR2 and TLR4-MD2-dependent activation. We hypothesized that human cationic host defense peptides
interact with CPS and influence its biologic activity. Accordingly, the interaction of meningococcal CPS with the human-
derived cationic peptide LL-37, which is expressed by phagocytic and epithelial cells that interface with meningococci
during infection, was investigated. LL-37 neutralized the pro-inflammatory activity of endotoxin-free CPS as assessed by
TLR2 and TLR4-MD-2-dependent release of TNFa, IL-6 and IL-8 from human and murine macrophages. The cationic and
hydrophobic properties of LL-37 were crucial for this inhibition, which was due to binding of LL-37 to CPS. LL-37 also
inhibited the ability of meningococcal CPS to induce nitric oxide release, as well as TNFa and CXCL10 (IP-10) release from
TLR4-sufficient and TLR4-deficient murine macrophages. Truncated LL-37 analogs, especially those that retained the
antibacterial domain, inhibited vaccine grade CPS and meningococcal CPS prepared from the major serogroups (A, B C, Y
and W135). Thus, LL-37 interaction with CPS was independent of specific glucan structure. We conclude that the capacity of
meningococcal CPS to activate macrophages via TLR2 and TLR4-MD-2 can be inhibited by the human cationic host defense
peptide LL-37 and propose that this impacts CPS-based vaccine responses.
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Introduction
Neisseria meningitidis is a strict human pathogen that can cause
both meningitis and fulminant septicemia. Frequently, disease
occurs in epidemics with substantial mortality such as been
observed in the sub-Saharan region of Africa (e.g., the so-called
‘‘meningitis belt’’) [1]. Prevention of meningococcal disease has
been a major public health effort for several years and the capsular
polysaccharides (CPS) produced by meningococci have served as
the basis for past and current vaccines. The CPS produced by N.
meningitidis are considered as major virulence factors because they
protect the bacteria from complement-mediated killing, as well
inhibiting phagocytosis by professional phagocytes [2,3]. The
different CPS structures expressed by N. meningitidis form the basis
for serogroup designation and protective vaccines [1,4].
Innate immune host responses are rapidly initiated following the
recognition of microbial molecules such as endotoxin, peptidogly-
can, lipoteichoiec acid, lipopeptides, zymosan and nucleic acids
expressing pathogen associated molecular patterns (PAMPs) or
endogenous ‘‘danger’’ molecules (DAMPS) release by damaged
cells [5,6]. The outcome of host-pathogen interactions frequently
leads to the release of pro-inflammatory mediators such as
cytokines, chemokines, eicosanoids, reactive oxygen species
(ROS) and host defense peptides. Host defense peptides have
been shown to possess antimicrobial and immunomodulatory
activities [7]. In this respect, we have shown that the sole human
cathelicidin termed LL-37 not only has anti-meningococcal
activity [8], but also interacts with meningococcal lipooligosac-
charide (LOS) and as a consequence, inhibits release of pro-
inflammatory mediators that is normally driven via a TLR4/MD2
receptor complex [9].
Recently, CPS from Bacteroidis fragilis [10] and Streptococcus suis
[11] were shown to be recognized by Toll-like receptor 2 (TLR2).
Based on these observations, we questioned whether meningo-
coccal CPS could modulate TLR-mediated responses and if such
responses are subject to regulation by host defense peptides. We
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13627found thatpreparations of meningococcal CPS inducethe release
of pro-inflammatory mediators from human and murine
macrophages via TLR2 and TLR4/MD-2 (S. Zughaier,
unpublished observations, and see below). Accordingly, the
pro-inflammatory properties of meningococcal CPS and modu-
lation by host defense peptides were investigated. LL-37 was used
as a model peptide because it has been invoked as an immune
modulator [7]. Understanding this interplay between CPS and
LL-37 in controlling innate immune responses is important
because possession of CPS is essential for invasive meningococcal
disease and intracellular survival [3,12]. Additionally, sublethal
levels of LL-37, which are likely to occur in vivo,h a v eb e e ns h o w n
to cause increased expression of meningococcal genes involved in
CPS biosynthesis [13]. Because LL-37 and other AMPs
participate in both clearance of invading pathogens and
detoxification of bacterial ligands (e.g., endotoxin and lipotei-
choic acid) possessing pro-inflammatory properties, the ability of
LL-37 and its synthetic analogs to block CPS-mediated pro-
inflammatory responses was determined. Using vaccine-grade
and endotoxin-free CPS, the host defense peptide LL-37 was
found to interact with meningococcal CPS and inhibit release
of pro-inflammatory mediators from human and murine
macrophages.
Results
Immuno-stimulatory activity of meningococcal capsular
polysaccharides is neutralized by LL-37
Meningococcal CPS polymers consist of distinct repeating
glucan units that vary in composition and linkage among invasive
serotypes [1]. Meningococcal CPS polymers are polyanionic due
to the negatively charged sialic acid residues found in many
invasive meningococcal serogroups (e.g. B, C, Y, W-135) or due to
the presence of phosphates in the serogroup A polymers [1,4,12].
The immuno-stimulatory activity (bioactivity) of meningococcal
CPS polymers (vaccine grade and laboratory prepared CPS) was
investigated in vitro using well established and characterized human
and murine cell lines [14]. CPS was purified from an endotoxin-
deficient serogroup B N. meningitidis lpxA mutant (designated CPS-
lpxA) and consists of (a2R8)-N-acetylneuraminic acid rendered
protein-, lipopeptide-, phospholipid- and nucleic acid-free by
digestion with proteinase K, DNAse and RNAse during the
extraction and purification procedures (see Methods). This CPS
induced a dose-dependent release of the pro-inflammatory
cytokines TNFa and IL-6 from THP-1, human macrophages-like
cells (Figure 1A and B), IL-8 from HEK-TLR2/6 stably
transfected cells (Figure 1C) and nitric oxide (NO) release from
Figure 1. LL-37 neutralized meningococcal CPS bioactivity and inhibited cytokine release from human and murine macrophages.
CPS polymers were purified from the endotoxin-deficient serogroup B meningococcal NMB-lpxA mutant designated CPS-lpxA. A: TNFa release from
human macrophage-like THP-1 cells induced overnight with CPS-lpxA polymers pre-incubated with or without 2 mg/ml of LL-37 for 30 min at 37uC
(Materials and Methods section). B. IL-6 release from THP-1 cells induced as in panel A. C. IL-8 release from HEK-TLR2/6 stably transfected cells
induced with CPS-lpxA as in panel A. TNFa,IL-6 and IL-8 release was measured by ELISA. D. Nitric oxide release from murine RAW 264.7 macrophages
induced with CPS-lpxA polymers as in panel A and measured by the Griess method as nitrite accumulation after 24 h of incubation at 37uC with 5%
CO2. Error bars represent 6SD from the mean of quadruplicate measurements. This experiment is representative of three independent experiments.
doi:10.1371/journal.pone.0013627.g001
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ability to induce macrophage activation, as assessed by release of
cytokines and NO, we concluded that the endotoxin-free
serogroup B CPS is bioactive in an LPS-independent manner;
other CPS polymers from serogroup A, C, Y and W-135 strains
were found to have a similar activity (see below).
Pre-incubation of the serogroup B meningococcal CPS-lpxA
polymers with the human cathelicidin LL-37 resulted in dramatic
attenuation of CPS bioactivity. Thus, pre-incubation of CPS-lpxA
with 2 mg/ml of synthetic LL-37 inhibited cytokines and nitric
oxide release from target cells in a dose-dependent manner
(Figure 1A–D). The positively charged LL-37 peptide, but not the
negatively charged analog LL-37R/D-K/E, neutralized the
capacity of CPS in inducing the release of pro-inflammatory
chemokine IL-8 (Figure 2A and Figure S3). Thus, the positive
charge of LL-37 was important to the ability to neutralize
meningococcal CPS polymers.
Importantly, LL-37 and certain analogs neutralized the
immuno-stimulatory activity of meningococcal CPS polymers
without evidence of cellular toxicity as assessed by Trypan Blue
exclusion and LDH release assays (13 and data not shown).
Vaccine grade CPS purified from a serogroup A strain consisting
of (a1R6)-N-acetyl-D-mannosamine-1-phosphate (designated
MAPS) was also used in our studies. IL-8 release from HEK/
TLR2/6 cells induced by MAPS was significantly reduced when
the CPS (MAPS) was pre-incubated with 2 mg/ml of LL-37
(Figure 2B). The results suggest that meningococcal CPS charge
rather than glucan structure or repeat unit of the CPS was
important for its interaction with LL-37. This hypothesis was
tested in subsequent experiments (see below).
The antibacterial domain of LL-37 is required for
interaction with meningococcal CPS polymers
The ability of synthetic LL-37 analogs (Table 1) to interact with
meningococcal CPS polymers and neutralize bioactivity or inhibit
cytokines and nitric oxide release was investigated. The antibac-
terial domain of LL-37 was previously described [15] and consists
of amino acid residues 17–32, which was confirmed in the present
study using N. gonorrhoeae as a target pathogen (Table S1). In a
dose-dependent manner, truncated LL-37 analogs that contain the
active domain amino acid sequences 17–32, but not residues 1–17
(inactive domain), neutralized endotoxin-free CPS immuno-
stimulatory activity as assessed by release of pro-inflammatory
mediators TNFa (Figure 3A) and IL-6 by target cells (Figure 3B).
Further, acylation with a highly nonpolar C12 alkyl moiety of a
truncated analog (C12LL17-32), as well as replacement of the
negatively charged residue, aspartic acid (D), with the polar, non-
charged residue, asparagine (N), C12LL17-32D/N analog,
enhanced interaction with meningococcal CPS polymers as
indicated by their ability to inhibit release of TNFa (Figure 3A)
and IL-6 (Figure 3B) from human THP-1 cells. The ability of
truncated LL-37 analogs to neutralize meningococcal CPS
polymers correlated with their antibacterial action (Table S1)
against N. gonorrhoeae, which naturally lacks CPS [16]. Taken
together, the data suggest that both charge and amphipathicity are
important for LL-37 analogs antibacterial activity and interaction
with meningococcal CPS polymers. Similarly, synthetic truncated
LL17-32 analogs inhibited CPS induced TNFa release (Figure 4A)
and nitric oxide release (Figure 4B) from murine RAW 264, a
TLR4-suficient macrophage cell line. An acylated, truncated
analog of LL-37 (C12LL17-32) also inhibited CPS-induced nitric
oxide release from murine ScCr, a TLR4-deficient macrophage
cell line (Figure 5).
Synthetic LL-37 analogs interaction with vaccine grade
meningococcal CPS
We hypothesized that because LL-37 can be produced by
professional immune cells, the ability of CPS-based bacterial
vaccines (conjugated and non-conjugated) to modulate innate
immunity responses might be influenced by LL-37. To test this
hypothesis, the interaction between meningococcal CPS polymers
and LL-37 and the truncated analogs (Table 1) was examined. For
this purpose, we used the MAPS CPS purified from serogroup A
N. meningitidis and compared it to laboratory-prepared CPS from a
serogroup A strain (NMA). Truncated LL-37 analogs that contain
the antibacterial domain (residues 17–32) inhibited both the
laboratory prepared NMA CPS and the vaccine grade meningo-
Figure 2. Cationic charge is important for LL-37 interaction
with CPS polymers. A: IL-8 release from HEK-TLR2/6 stably
transfected cells induced with serogroup A meningococcal CPS
polymers pre-incubated with 4 mg/ml of either LL-37 parent analog or
the negatively charged LL-37R/D-K/E (LL-37-ve) analog used as a
control. B: IL-8 release from HEK/TLR2/6 cells induced with a vaccine
grade CPS purified from N. meningitidis serogroup A (MAPS) pre-
incubated with or without 4 mg/ml of synthetic LL-37 parent analog.
TLR2/6-ve is unstimulated HEK-TLR2/6 stably transfected cells. IL-8
measured by ELISA. Error bars represent 6SD from the mean of
quadruplicate measurements. This experiment is representative of two
independent experiments.
doi:10.1371/journal.pone.0013627.g002
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RAW 264 macrophages (Figure S1A and S1B). Similar reductions
in TNFa (Figure S1C) and IL-6 (data not shown) release from
THP-1 cells were seen. Synthetic LL-37 variants inhibited
commercial MAPS CPS similar to the laboratory purified
meningococcal CPS polymers. Cationic peptides such as synthetic
LL-37 variants and polymyxin B inhibited CPS polymers, but this
was not seen with ampicillin, a classical zwitterion (Figure S1B).
The cationic nature of LL-37 was anticipated to be a critical
determinant in the ability of LL-37 to interact with CPS and
neutralize its bioactivity. To test this, a synthetic LL-37 analog
(LL-37K/E), where all positively charged lysine (K) residues were
replaced with the negatively charged acidic residue glutamic acid
(E), was examined for its ability to inhibit the pro-inflammatory
capacity of CPS. This peptide showed reduced neutralizing
activity against purified CPS polymers. The reduced ability of
LL-37K/E to interact with purified CPS correlated with reduced
bactericidal activity against gonococcal strain FA19 (Table S1)
where the LL-37 MIC is =7.8 mg/ml and the LL-37K/E MIC is
.1000 mg/ml. In contrast, the replacement of all cationic and
anionic residues by lysine (LL-37K) or arginine (LL-37R) did not
enhance the neutralizing activity of the analog against purified
CPS polymers, but retained excellent MIC activity against
gonococci (Table S1).
LL-37 analogs interact with CPS from various
meningococcal invasive serogroups
Since the meningococcal capsule is the basis for serogroup
designation, we tested whether interaction of LL-37 analogs with
CPS was dependent on capsule structure. Laboratory prepared
CPS polymers from invasive meningococcal strains A, B, C, Y and
W135 were tested in the TLR4-deficient macrophage cell line
ScCr to eliminate the contribution from any LPS contamination in
the preparations. Twenty micrograms of the CPS polymers were
pre-incubated with 4 mg/ml of LL-37 analogs for 30 min, then
used to stimulate ScCr cell overnight; as controls, CPS polymers
were also pre-incubated with 20 mg/ml of ampicillin or erythro-
mycin. Truncated and acylated LL-37 analogs significantly
reduced nitric oxide release induced by various meningococcal
CPS (Figure 6); this inhibition was not observed with ampicillin
and erythromycin. Similar results were seen in epithelial HEK/
TLR2/6 transfected cells stimulated with different meningococcal
CPS structures. Pre-incubation with LL-37 resulted in a significant
reduction in IL-8 release. Taken together, the data indicate that
LL-37 interaction with meningococcal CPS polymers is indepen-
dent of the repeating carbohydrate unit structure in CPS, but is
more likely a reflection of the negative charge of meningococcal
CPS polymers.
Synthetic LL-37 analogs decrease NFkB activation
induced with meningococcal CPS
The neutralizing activity of LL-37 analogs against meningo-
coccal CPS was confirmed in human epithelial HEK/TLR2/6
cells transfected with the inducible NFkB dual luciferase reporter.
Pre-incubation of meningococcal endotoxin free CPS polymers
(20 mg/ml) with synthetic LL-37 analogs (4 mg/ml) for 30 min
prior to cellular stimulation resulted in attenuation of the NFkB
inducible luciferase reporter (Figure 7A). The truncated LL-37
analogs that contain the active domain LL-17-32 as well as the
acylated C12LL17-32 molecule and polymyxin B (PMX) were
able to inhibit meningococcal CPS induced NFkB induction and
decreased TNFa release (Figure 7B).
Meningococcal CPS polymers bind to LL-37
LL-37 and other cationic peptides havethe ability to bind LPS by
virtue of their cationic and hydrophobic properties [17]. To test if
LL-37 and CPS can form a complex, we employed an
electrophoretic mobility shift assay (EMSA) to resolve potential
CPS:LL-37 complexes. Since CPS polymers are hydrophilic and
highly water soluble, CD14 and LBP were used to stabilize the
carbohydrate polymers for the EMSA assay [18]. Complexes were
Figure 3. LL-37 active domain is required for interaction with
meningococcal CPS polymers. Acylation and charge of truncated
LL-37 analogs enhanced interaction with meningococcal CPS polymers
and inhibited TNFa(A) and IL-6 (B) release in a dose-dependent manner.
THP-1 cells stimulated with meningococcal serogroup B, endotoxin-free
CPS-lpxA doses ranging from 100 mg to 50 ng/ml with or without
10 mg/ml synthetic LL-37 analogs. LL-37-ve is negatively charged analog
LL-37 K/E-R/D used as a control. TNFa and IL-6 release was quantified by
ELISA. Error bars represent 6SD from the mean of quadruplicate
readouts. The results are representative of 4 independent experiments.
doi:10.1371/journal.pone.0013627.g003
Table 1. Synthetic LL-37 variants amino acid sequences.
LL-37 L
1LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
37
LL-37R/D-K/E (-ve) L
1LGDFFDESEEEIGEEFEDIVQDIEDFLDNLVPDTES
37
LL-37 R/D L
1LGDFFDKSKEKIGKEFKDIVQDIKDFLDNLVPDTES
37
LL-37 K/E L
1LGDFFRESEEEIGEE FERIVQRIEDFLRNLVPRTES
37
LL-37 K/A L
1LGDFFRASAEAIGAE FARIVQRIADFLRNLVPRTES
37
LL-37 K L
1LGKFFKKSKKKIGKKFKKIVQKIKKFLKNLVPKTKS
37
LL-37 R L
1LGRFFRRSRRRIGRRFRRIVQRIRRFLRNLVPRTRS
37
LL 17-32 F
17KRIVQRIKDFLRNLV
32
LL 17-32D/N F
17KRIVQRIKNFLRNLV
32
C12LL 17-32D/N dodecanoyl-F
17KRIVQRIKNFLRNLV
32
LL 11-37 E
11KIGKE FKRIVQRIKDFLRNLVPRTES
37
LL 1-17 L
1LGDFFRKSKEKIGKEF
17
doi:10.1371/journal.pone.0013627.t001
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biotinylated anti-LBP and anti-CD14 antibodies to detect the
complexes. Both CD14 and LBP were required to stabilize CPS
complexes and visualize the shift. The additions of LL-37 to CPS-
lpxA-CD14-LBP complexes caused a gel-shift (Figure 8, lane 5)
compared to CPS-lpxA-CD14-LBP complexes (Figure 8 lane 3), to
CD14-LBP alone (Figure 8, lane 4) and to LL-37-CD14-LBP
complexes (Figure 8, lane 6). The bioactivity of the CPS-lpxA
complexes used in gel-shift was further confirmed using RAW 264
macrophages. In contrast to CPS-lpxA complexes alone or with
CD14 and LBP that were very active and induced large nitric oxide
release, CPS-lpxA complexes that contained LL-37 gel-shifted in
lane 5, showed significant reduction in nitric oxide release (data not
shown).The results demonstratethat LL-37 bindsto meningococcal
CPS-lpxA polymers intheabsence ofendotoxinandthat this specific
interaction results in decreased CPS immuno-stimulatory activity.
Thus, the interaction of this host-derived peptide with meningo-
coccal CPS modulates innate immune responses.
Figure 4. LL-37 active domain is required for interaction with meningococcal CPS polymer and inhibited immune responses in
murine macrophages. A: Mouse TNFa release from murine RAW 264 macrophages induced with 20 mg /ml serogroup B meningococcal CPS-lpxA
polymers pre-incubated with 2 mg/ml synthetic LL-37 analogs for 30 min at 37uC prior to cellular induction. B: Nitric oxide release from stimulated
RAW 264.7 used in panel A was quantified by the Greiss method. Error bars represent the 6SD from the mean of 4 independent wells. The results are
representative of 2 independent experiments.
doi:10.1371/journal.pone.0013627.g004
Figure 5. LL-37 interaction with meningococcal CPS polymer is TLR4-independent. Nitric oxide release from murine ScCr (TLR4-deficient)
cells induced with with 20 mg /ml serogroup B meningococcal CPS-lpxA polymers pre-incubated with 2 mg/ml synthetic LL-37 analogs for 30 min at
37uC prior to cellular induction. PMX: polymyxin B; Pam3CSK4: synthetic lipopeptide and a TLR2 ligand used as a control at 2 mg/ml final
concentration. Error bars represent the 6SD from the mean of 4 independent wells. The results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0013627.g005
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Bacterial capsular polysaccharides (CPS) have been extensively
studied as virulence factors due to their ability to impede organism
clearance by host antimicrobial systems, such as phagocytosis by
professional phagocytes and complement mediated killing. Bacte-
rial CPS also form the basis for vaccines including those that
protect against serogroups A, C, Y and W-135 meningococci [1].
Increasing evidence also suggests that CPS functions as an
immune modulator with pro-inflammatory activities similar to
other bacterial products (e.g., endotoxin). Indeed, results presented
herein demonstrate that laboratory-prepared meningococcal CPS
devoid of LPS can activate human and murine macrophages as
assessed by release of cytokines and NO through TLR2- and
TLR4-MD2 dependent pathways. This activation of pro-inflam-
matory signaling pathways can result in release of immune
modulators (e.g., cytokines, chemokines, NO and ROS) that can
impact severity of disease (e.g., sepsis and meningitis). Also, there is
increasing evidence that cationic antimicrobial peptides that are
constitutively produced by phagocytes or inducibly synthesized by
epithelial cells can dampen the ability of bacterial ligands (e.g.,
endotoxin and LTA) to amplify innate immune responses [7,17].
To our knowledge, this is the first report of a host defense peptide
(LL-37) that has the ability to dampen the immune-stimulatory
activity of bacterial CPS.
Extensive efforts were made to eliminate other TLR ligands in
all CPS preparations which might have confounded the results.
These efforts included digestion of samples with proteinase K,
DNAse and RNAse treatments, ultracentrifugation, gel filtration,
and extensive dialysis that are expected to remove low-MW
compounds and retain large CPS polymers. The purity of CPS
preparations was also demonstrated by Alcian blue and silver
staining [19] of PAGE gels containing CPS preparation (data not
presented). Further, CPS extraction from the LOS-deficient
meningococci was performed in parallel to a phospholipid
extraction (designated PL-lpxA) from the same GC broth. In
contrast to CPS-lpxA, PL-lpxA induced a TLR2-mediated
response, but LL-37 failed to neutralize its biologic activity. Thus,
TLR ligand contamination in these preparations was ruled out.
Using synthetic analogs of the amphipathic, alpha-helical LL-37
peptide, we observed that the cationic and hydrophobic properties
are important characteristics in the ability to detoxify or neutralize
Figure 6. Meningococcal CPS serogroups A, B, C, Y and W135 interact with LL-37 analogs. Laboratory prepared meningococcal CPS
polymers (20 mg/ml) from invasive meningococcal serogroups were pre-incubated with 4 mg/ml of LL-37 analogs and used to stimulate ScCr (TLR4-
deficient) murine macrophages overnight. A- NMA CPS is meningococcal serogroup A CPS; B- NMB CPS is meningococcal serogroup B; C- NMC CPS
is meningococcal serogroup C CPS; D- NMY CPS is meningococcal serogroup Y CPS and E- W135 CPS meningococcal serogroup W135 CPS. Nitric
oxide release was measured as nitrite accumulation in the supernatants using the Greiss method. A non-cationic antibiotics ampicillin and
erythromycin were used at 20 mg/ml as controls. Error bars represent the 6SD from the mean of 4 independent wells. This is representative of three
independent experiments.
doi:10.1371/journal.pone.0013627.g006
Figure 7. Synthetic LL-37 inhibited NFkB activation and TNFa release by meningococcal CPS-lpxA polymers. A: Inducible NFkB dual
luciferase reporter transfected into HEK-TLR2/6 stably transfected cells then stimulated with serogroup B meningococcal CPS-lpxA with or without LL-
37 analogs. CPS-lpxA polymer (100 mg) was pre-incubated with 10 mg of LL-37, C12-LL17-32 or polymyxin B (PMX) prior to cellular induction for 5 h.
Inducible NFkB firefly luciferase activity was normalized to constitutively expressing Renilla luciferase reporter. Negative control is transfected with
non-inducible firefly luciferase reporter. Positive control is a mixture of constitutively expressing GFP and firefly luciferase construct. B: TNFa release
from human THP-1 cells induced with CPS-lpxA-LL-37 analog prepared complexes used in panel A. TNFa protein was quantified by ELISA and error
bars represent 6SD from the mean of 4 independent wells. This experiment is representative of three independent determinations.
doi:10.1371/journal.pone.0013627.g007
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by residues 17–32) of LL-37 was required for detoxification of
CPS. Importantly, LL-37 and its truncated analogs did not impact
the viability of human or murine macrophage at concentrations
that were effective in detoxifying CPS. The capacity of LL-37 to
detoxify CPS required electrostatic and hydrophobic interactions.
Indeed, LL-37 analogs that differed in their cationic and/or
hydrophobic properties differed in their ability to neutralize CPS.
Truncated and acylated LL-37 analogs neutralized meningococcal
CPS immuno-stimulatory activity and inhibited cytokine release
and inflammatory mediators by inhibiting NFkB activation. Thus,
no selective inhibition or induction of signaling pathways like the
MyD88 or TRIF-dependent pathway was observed. Pre-treatment
of macrophages with LL-37 for 30 min followed by washing to
remove LL-37 prior to stimulation with meningococcal CPS
polymers did not affect cytokine release (Figure S2). Thus, the
complexes formed between LL-37 and meningococcal CPS
polymers lead to the neutralization of immuno-stimulatory activity
and decreased cytokine release.
In support of our findings and conclusions, Foschiatti et al. [20]
recently used circular dichroism, fluorescence spectroscopy and
atomic force microscopy to demonstrate the direct bindingof LL-37
to exopolysaccharides of Pseudomonas aeruginosa and Burkholderia
cepacia complex. The negative charges of exopolysaccharides were
found to be important for complex formation with LL-37 and the
binding was through electrostatic and other non-covalent interac-
tions [20]. The impact of LL-37 binding to polysaccharides was also
demonstrated in an animal model of Pseudomonas sinusitis biofilm,
where a high concentration of LL-37 derived peptide was shown to
eradicate Pseudomonas biofilms and decrease bacterial viability [21].
Using an EMSA procedure, we confirmed the ability of
meningococcal CPS polymers to directly bind LL-37. Meningo-
coccal CPS are negatively charged polymers and meningococci are
highly resistant to AMPs [8]. Host cationic peptides contribute to
bacterial killing directly by destabilizing bacterial membranes [7] or
by forming phagocyte extracellular traps (ETs). These traps are
formed when AMPs bind to host DNA, histones and proteases to
form a matrix that entraps and kills invading pathogens [22]. Thus,
LL-37 bindingtoanionicCPSpolymers maydepletetheavailability
of these peptides to form ETs or even to penetrate and reach their
bacterial membrane target.
In addition to their direct antimicrobial action, host cationic
peptides such as LL-37 can also modulate various immune
responses and in some cases lead to pathological consequences.
For example, Lande et al. reported that LL-37 coupled with self-
DNA released from necrotic host cells induced plasmacytoid
dendritic cells that drove autoimmunity in psoriasis [23]. In a
more recent study the same authors found that self-RNA also
complex with LL-37 and induce TLR7 and TLR8 [24]. DNA and
RNA molecules are highly negatively charged (polyanionic) and
thus would electrostatically bind to LL-37. Sandgren et al.
demonstrated that LL-37 facilitates transfer of extracellular DNA
plasmid to the nuclear compartment of mammalian cells via lipid
rafts and endocytosis [25]. Further, LL-37 has been shown to
complex with polyanionic DNA and F-actin bundles accumulated
in cystic fibrosis airway fluid, thus leading to inactivation of these
cationic peptides [26,27]. In further support, Hurtado et al.
reported the rapid interaction of LL-37 with bacterial DNA
unmethylated CpG oligonucleotides motifs that contain the
negatively charged phosphodiesters and phosphorothionate back-
bones. They concluded that LL-37 aids the delivery of CpG motifs
to the endosomal compartment and rapidly induced TLR9 in B
lymphocytes and plasmacytoid dendritic cells [28]. Other recent
studies have documented a role for host-derived cationic peptides
in gut homeostasis [29,30]. Microbiota, although symbiotically
living in the bowel, continuously shed capsular polysaccharides.
The shed capsular polymers are neutralized and degraded by an
unknown mechanism. Thus, it is possible that cationic peptides
released from the gut mucosal surfaces to the lumen bind to CPS
and play a key role in dampening inflammation and maintaining
homeostasis, hence the physiological role of LL-37 in keeping gut
inflammation at bay [31,32]. Taken together, LL-37 can form
complexes with various pathogen-derived anionic polymers
leading to immune response modulation.
In summary, LL-37 and certain analogs modulate the capacity of
meningococcal CPS polymers to induce innate immune responses.
Figure 8. Electrophoretic mobility gel shift assay of meningococcal CPS-lpxA polymers in the presence of LL-37, LBP and CD14. CPS-
lpxA complexes were prepared as described in the Methods section, were run on 8% native PAGE, and detected by Western blot using biotinylated
LBP antibody. Lane 1 (MWt): molecular weight marker; lane 2 CPS-lpxA alone; lane 3: CPS-lpxA-CD14-LBP; lane 4: CD14-LBP alone; lane 5: CPS-lpxA-
LL-37-CD14-LBP; lane 6: LL-37-CD14-LBP; lane 7: CPS-lpxA-LL-37 alone.
doi:10.1371/journal.pone.0013627.g008
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considered in the future as a therapeutic option for dampening the
pathologic consequences of inflammation and sepsis.
Materials and Methods
Reagents
RPMI 1640 medium, Dulbecco’s Eagle medium, fetal bovine
serum (FBS), penicillin/streptomycin, sodium pyruvate and
nonessential amino acids were obtained from Cellgro Mediatech
(Herndon, VA). Polymyxin B, ampicillin, and erythromycin were
purchased from Sigma Chemical (St. Louis, MO). Phorbol
myristate acetate (PMA) was purchased from GibcoBRL (Grand
Island, NY). Human and mouse TNFa IL-8, IL6 and IP-10
ELISA kits were from R&D Systems (Minneapolis, MN). THP-1,
RAW 264.7, and 23ScCr (TLR4-deficient) cell lines were
purchased from ATCC (Mannasas, VA). Basticidin, human
embryonic kidney 293 HEK-TLR2/6 and HEK-TLR2 stably
transfected cells were purchased from InvivoGen (San Diego, CA).
HEK-TLR2/CD14 stably transfected cell line was provided by
Dr. Evelyn Kurt-Jones (University of Massachusetts Medical
Center, Worcester, MA).
Cationic peptides
The solid-phase peptide synthesis of LL-37 and its analogs
(Table 1), used in this study, has been previously described [17].
The peptides were purified to .98% chromatographic homoge-
neity by reversed-phase HPLC on C18-silica packings and were
obtained in the form of their trifluoroacetate salts; their masses
were confirmed by MALDI-TOF mass spectrometry. The
peptides were dissolved in 0.01 % (v/v) acetic acid and stored at
220uC prior to use. Antibacterial assays were performed as
described previously [33] and used N. gonorrhoeae strain FA 19. All
assays were performed in triplicate and values are reported as the
minimal inhibitory concentration (MIC).
Capsular polysaccharide purification
CPS was purified from an endotoxin-deficient serogroup B
Neisseria meningitidis mutant (NMB-lpxA) and from other meningo-
coccal serogroups like A, B, C, W135 and Y as previously
described [34]. Briefly, bacteria were grown in 3 liters of GC broth
for 16 hours and CPS was released by lysing with 10% of Cetavlon
(hexadecyl-trimethyl ammonium bromide) added to a final
concentration of 1.0%. The precipitate and bacterial debris were
collected by centrifugation (11,000 6 g for 15 min) and then
resuspended in 50 ml of distilled water. CPS-Cetavlon complexes
were dissociated with 1 volume of 2 M CaCl2 and stirring for 1 h.
Nucleic acids were precipitated with absolute ethanol and
removed by centrifugation. CPS were precipitated by 80%
ethanol, washed 3 times with acetone and twice with diethyl ether
and dried by vacuum. Contaminating proteins and phospholipids
were removed and the purified CPS was further subjected to
proteinase K digestion, DNAse and RNAse treatment followed by
extensive dialysis [19]. Vaccine grade CPS (MAPS) was a gift from
Dr. Seshu Gudlavalleti, the Center for Biologics, FDA (now at GN
International Medical Corp. Omaha, NE).
Cell cultures
THP-1, human macrophage-like cells were grown in RPMI
1640 with L-glutamate supplemented with 10% FBS, 50 IU/ml of
penicillin, 50 mg/ml of streptomycin, 1% sodium pyruvate and 1%
non-essential amino acids. Culture flasks were incubated at 37uC
with humidity under 5% CO2. Murine macrophages (RAW 264.7
and 23ScCr) and human kidney epithelial cells HEK293 were
grown in Dulbecco’s Eagle medium supplemented and incubated
as noted above.
Cellular activation
Human THP-1 (macrophage-like cells) and murine RAW 264.7
(TLR4-sufficient), 23ScCr (TLR4-deficient) and HEK-TLR2/6/
CD14 stably transfected cell lines were stimulated with meningo-
coccal CPS polymers with or without pre-incubation with LL-37
and its analogs (Table 1). CPS polymers were purified from the
LPS-deficient serogroup B Neisseria meningitidis lpxA mutant as well
as other meningococcal serogroups A, B, C, W135 and Y. Purified
CPS samples were freshly dissolved in pyrogen-free sterile H2Oa t
1 mg/ml stock concentration and vortexed for 2 min. Working
CPS concentrations (ranging from 100 mg/ml to 50 ng/ml) were
made in duplicate wells using sterile PBS by serial fold dilutions in
the 96-well tissue culture plates (Becton Dickinson, Franklin Lakes,
NJ) at 50 ml final volumes. Cationic peptides (2, 4 or 8 mg/ml) or
PBS equivalent volumes were added to designated wells and pre-
incubated for 30 min at 37uC. Freshly grown THP-1 cells and
HEK-TLR2/6 transfected cells as well as murine macrophages,
each adjusted to 10
6 cell/ml and 250 ml aliquots were dispensed
into each well at final 250610
3 cell density in the designated 96-
well plates. The plates were incubated overnight at 37uC with 5%
CO2 and humidity. Supernatants from stimulated cells were
harvested and stored at 220uC until use.
Cytokine profiles
The cytokines TNFa, IL-6 and CXCL10 (IP-10), released from
THP-1 cells, and IL-8, released from HEK-TLR2 transfected cells
stimulated with meningococcal CPS polymers, were quantified by
DuoSet ELISA (R&D Systems) as previously described [14].
Nitric oxide induction by murine macrophages
Freshly grown adherent RAW 246.7 or 23ScCr (TLR4-
deficient) macrophages were harvested, washed and re-suspended
in Dulbecco’s complete media, counted and adjusted to 10
6 cell/
ml. 250 ml aliquots were then dispensed into each well of a 96-well
plate at final 250610
3 cell density prior to stimulation with
purified CPS polymers with or without cationic peptides. The
induced RAW 264.7 or 23ScCr macrophages were incubated
overnight at 37uC with 5% CO2 and supernatants were harvested
and saved. Nitric oxide release was quantified using the Greiss
chemical method as previously described [9].
Cell-based multi pathway activity assay
To determine the signaling pathways induced upon meningo-
coccal CPS recognition, a transcription factors array (Cignal
Finder
TM 10-Pathway Reporter Arrays, SABiosciences, Fredrick,
MD) consisting of 10 dual-luciferase reporters assays were used
according to the manufacturer instructions. Each of the 10
reporter assays encodes for an inducible transcription factor
responsive firefly luciferase reporter and constitutively expressing
Renilla construct in 40:1 ratio. Briefly, DNA reporter master mixes
were prepared in SureFect transfection reagent (SABiosciences)
diluted in Opti-MEM media without serum or antibiotics and
25 ml/well were dispensed into 96-well white tissue culture plates.
For reverse transfection, freshly grown cells were counted and
adjusted to 1610
6 cells/ml in Opti-MEM without serum or
antibiotics. 100 ml of cells (100610
3 cells/well) were laid over the
DNA reporters in 96-well plates and incubated overnight at 37uC
with 5% CO2. Transfection media were removed and replaced
with 150 ml of fresh D-MEM supplemented with 10% FBS and
incubated again overnight at 37uC. Cells were then induced with
LL-37 Inhibits CPS Recognition
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luciferase reporter activity was determined using Dual-Luciferase
reporter assay system (Promega Corporation, Madison, WI)
following the manufacturer instructions. Induced transcription
factors were reported as firefly luciferase activity normalized to
Renilla luciferase activity.
Electrophoretic mobility shift assay (EMSA) of CPS
complex with LL-37, CD14 and LBP
To assess binding of CPS to LL-37 in the presence of human
CD14 and LBP, an EMSA assay using native gel conditions was
performed [18]. Serogroup B CPS purified from a LOS-deficient
meningococcal lpxA strain were dissolved in sterile H2O at 1 mg/
ml concentration and 20 ml were transferred into an Eppendorf
tube mixed with 10 ml( 5mg) of LL-37, 10 ml (0.5 mg) of human
rCD14 and 10 ml (0.5 mg) of rLBP (R&D Systems) in 30 ml final
volume and incubated for 3 h at 37uC. An aliquot of 7.5 ml of the
mixed complexes were transferred into a new Eppendorf tube and
mixed with an equal volume of sample buffer (0.1 M Tris-glycine
buffer containing 20% glycerol and bromophenol blue) and 15 ml
of the mixture were loaded on 8% native polyacrylamide gel
electrophoresis (PAGE) without SDS as previously described [18].
Electrophoresis was performed with Tris-glycine buffer pH 8.8
without SDS and run for 2 h at 4uC. The gel-shifting of CPS
complexes was detected by Western blot method using biotiny-
lated anti CD14 and anti LBP antibodies (R&D Systems) diluted
1:15006with blocking buffer.
Statistical analysis
Mean values 6 SD and P values (Student t test) of at least four
independent determinations were calculated with Microsoft Excel
software.
Supporting Information
Figure S1 Synthetic LL-37 analogs interact with a vaccine grade
meningococcal CPS. Murine RAW 264 macrophages stimulated
with (A) laboratory prepared serogroup A meningococcal CPS
polymers or (B) a vaccine grade serogroup A meningococcal CPS
20 mg /ml (MAPS) pre-incubated with or without 4 mg/ml of
synthetic LL-37 analogs. Ampicillin, a non-cationic antibiotic, was
used as a control. Nitric oxide release from induced murine cells
was quantified by the Griess method as nitrite accumulation after
24 h of incubation at 37uC with 5% CO2. RAW-ve is
unstimulated cells but 50 ml of equivalent PBS volume is added.
C: TNFa release from human THP-1 cells stimulated with
laboratory prepared meningococcal serogroup A CPS polymers
pre-incubated with LL-37 analogs as in panel A. Error bars
represent the 6SD from the mean of 4 independent wells. The
results are representative of three independent experiments. * p
values were calculated using Excel software student t-test in
reference to CPS alone without LL-37 analogs.
Found at: doi:10.1371/journal.pone.0013627.s001 (6.85 MB TIF)
Figure S2 Pre-treatment of macrophages with LL-37 did not
alter cellular responses. Murine macrophages RAW 264 were pre-
treated with 10 mg/ml of LL-37 or its inactive analog (the
negatively charged LL-37-ve) for 30 min, followed by washing to
remove LL-37 prior to stimulation with meningococcal LOS doses
(A) or CPS-lpxA dose of 50 mg/ml (B). Nitric oxide release was
measured as nitrite accumulation in supernatants and quantified
by the Greiss method.
Found at: doi:10.1371/journal.pone.0013627.s002 (0.60 MB TIF)
Figure S3 LL-37 interacts with meningococcal CPS and inhibits
IL-8 release from HEK/TLR4-MD-2-CD14 stably transfected
cells. IL-8 release from HEK/TLR4-MD-2-CD14 stably trans-
fected cells induced with serogroup B meningococcal CPS-lpxA
polymers pre-incubated with 4 mg/ml of LL-37. IL-8 was
measured by ELISA method.
Found at: doi:10.1371/journal.pone.0013627.s003 (0.29 MB TIF)
Table S1 L: leucine; K: lysine; R: arginine; E: glutamic acid; D:
aspartic acid; A: alanine; N: asparagine FA19: non-encapsulated
Neisseria gonorrhea MIC: minimal inhibitory concentration. NA: not
available.
Found at: doi:10.1371/journal.pone.0013627.s004 (0.04 MB
DOC)
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